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Recent Zika virus (ZIKV) outbreaks have highlighted the necessity
for development of novel vector control strategies to combat
arboviral transmission, including genetic versions of the sterile
insect technique, artificial infection with Wolbachia to reduce pop-
ulation size and/or vectoring competency, and gene drive-based
methods. Here, we describe the development of mosquitoes syn-
thetically engineered to impede vector competence to ZIKV. We
demonstrate that a polycistronic cluster of engineered synthetic
small RNAs targeting ZIKV is expressed and fully processed in Aedes
aegypti, ensuring the formation of mature synthetic small RNAs in
the midgut where ZIKV resides in the early stages of infection. Crit-
ically, we demonstrate that engineered Ae. aegyptimosquitoes har-
boring the anti-ZIKV transgene have significantly reduced viral
infection, dissemination, and transmission rates of ZIKV. Taken to-
gether, these compelling results provide a promising path forward
for development of effective genetic-based ZIKV control strategies,
which could potentially be extended to curtail other arboviruses.
ZIKA | resistance | Aedes | aegypti | mosquito
Since being introduced into the Americas, Zika virus (ZIKV), amosquito-borne flavivirus, has spread rapidly, causing hun-
dreds of thousands of cases of ZIKV infection (1). Although most
cases remain asymptomatic, infection during pregnancy has been
associated with severe congenital abnormalities and pregnancy
loss, presenting an unprecedented health threat with long-term
consequences (2). This prompted the WHO to declare ZIKV a
public health emergency of international concern in 2016 (1, 2).
Currently, there are no clinically approved vaccines to prevent
ZIKV and no effective treatment options for infected individ-
uals; thus, vector control remains essential in curtailing the
ZIKV epidemic. Like dengue virus (DENV) and chikungunya vi-
rus (CHIKV), ZIKV is transmitted primarily by Aedesmosquitoes,
which are expanding their habitable range due to urbanization,
climate change, and global trade (3). Current methods of vector
control, including removal of standing water and use of insecti-
cides, have not been entirely effective in the fight against the
spread of Aedesmosquitoes (3). Therefore, novel innovative vector
control strategies, including those utilizing genetically engineered
mosquitoes (4), are urgently needed to combat the spread of ZIKV
and other Aedes-vectored diseases worldwide.
Employment of genetically modified (or otherwise altered)
insects to manipulate disease-vectoring populations was first
proposed decades ago (5), and due, in part, to enabling tech-
nological advances, it has garnered increased interest in recent
years (4, 6). In fact, several strategies for genetic-based vector
control are currently being utilized in the field. For example, the
release of insects carrying a dominant lethal system (7), a
genetic-based sterile insect technique-like system, has recently
been shown to be effective in reducing wild insect populations
(8). Open field release trials of these genetically modified
mosquitoes have been conducted in several countries, including
the Cayman Islands, Malaysia, and Brazil, and are currently
being considered for use in India and the United States (9–11).
In addition to genetic-based vector control strategies, mosqui-
toes harboring artificially acquired strains of Wolbachia can be
used either to reduce total insect populations (12) or to render
insect populations less competent vectors of certain viruses, in-
cluding ZIKV (13), and this technique has also been trialed in
multiple countries to reduce the impact of mosquito-borne dis-
eases (14–16) [although the accumulating evidence that Wolba-
chia can enhance certain flavivirus infections (17–19) may lead to
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reevaluation of this technique]. Nevertheless, while current ap-
proaches can be effective, they require inundative releases of
large numbers of insects, which can be laborious and expensive,
and can impede scalability and worldwide adoption.
Another category of genetic-based vector control involves an
engineered gene drive system that can force inheritance in a super-
Mendelian fashion, enabling it to increase itself, and any linked
“cargo” genes, in frequency with each generation even without
conferring fitness advantages to its host (4, 20). Such a method
could be used to disseminate desirable cargo genes, such as
pathogen resistance, rapidly through wild disease-transmitting
populations, modifying vector populations to be disease-
refractory (21). While significant efforts are currently underway
to develop engineered drive systems (22–25), others are focused on
creation of cargo genes that may be spread by the drive systems,
and several studies have reported on the successful development of
pathogen resistance cargo genes in Aedes aegypti (26–28).
To date, however, no anti-ZIKV refractory cargo genes in any
mosquito have been developed. To fill this void, we describe here
the generation of a synthetically engineered ZIKV resistance
transgene comprising a polycistronic cluster of ZIKV-targeting
synthetic small RNAs. We demonstrate that Ae. aegypti mos-
quitoes harboring this anti-ZIKV transgene express and fully
process the ZIKV-targeting synthetic small RNAs in the midgut,
and consequently have significantly reduced viral infection, dis-
semination, and transmission rates of ZIKV. Specifically, we
demonstrate that mosquitoes homozygous for the anti-ZIKV
transgene are fully resistant to ZIKV infection and are unable
to transmit the virus. In contrast, we determine that a minority of
heterozygotes for the anti-ZIKV transgene can become infected
with ZIKV following exposure. However, these heterozygotes
become infected at significantly lower rates than wild-type (WT)
mosquitoes, and those susceptible to infection have roughly
three orders of magnitude lower viral titers in their saliva, sug-
gesting a significantly reduced possibility of viral transmission.
This is supported by our finding that heterozygous anti-ZIKV
mosquitoes are almost entirely incapable of in vivo ZIKV
transmission in a sensitive Stat1−/− mouse model. Moreover,
compared with Wolbachia wMel strain-positive mosquitoes,
which have previously been shown to have reduced ZIKV vec-
toring competency (13), the anti-ZIKV mosquitoes perform
significantly better in the ZIKV challenge assays. Taken to-
gether, these compelling results provide a promising path
forward for development of effective ZIKV control, and
possibly control of other clinically significant arboviruses, us-
ing genetically engineered mosquitoes.
Results
Engineering ZIKV-Resistant Mosquitoes. To generate a cargo gene
that can confer resistance to ZIKV, we implemented a synthetic
small RNA-based approach, since such an approach has previously
been demonstrated to generate virus resistance phenotypes in a
number of contexts (e.g., refs. 29–31), including mosquitoes (32).
We engineered a piggyBac vector comprising a polycistronic cluster
of eight ZIKV-targeting, miRNA-like, synthetic small RNAs (the
anti-ZIKV transgene) under control of the Ae. aegypti carboxy-
peptidase (CPA) promoter (33) to drive expression of the synthetic
small RNAs in female midguts following a blood meal (Fig. 1A).
To ensure effective viral suppression and evolutionary stability, we
designed each of the eight synthetic small RNAs to target six of 10
conserved protein-coding genes of French Polynesia ZIKV strain
H/PF/2013 (GenBank accession no. KJ776791.2) (34), including all
three structural genes (capsid, membrane precursor, and envelope)
and three nonstructural genes (NS1, NS2A, and NS5). Each of
these genes was targeted by a single synthetic small RNA, except
for the RNA-dependent RNA polymerase NS5, which was tar-
geted by three small RNAs due to its importance for the replica-
tion of the flaviviral RNA genome (Fig. 1B and SI Appendix, Fig.
S1). The engineered anti-ZIKV transgene (termed plasmid
OA959C) also contained the eye-specific 3xP3 promoter (35)
driving expression of tdTomato as a transgenesis marker (Fig. 1).
Following embryonic microinjection, multiple transgenic lines were
identified (n> 6), and four independent lines with strong expression of
tdTomato fluorescence in the eyes (termed TZIKV-A, TZIKV-B,
TZIKV-C, and TZIKV-D) were selected for further characteriza-
tion (fluorescence in TZIKV-C is shown in Fig. 1C). To verify the
transgene insertion sites, we performed an inverse PCR (iPCR)
on genomic DNA extracted from transgenic mosquitoes of all
four independent strains. The iPCR analysis indicated that in-
sertion sites were on chromosome 2 (at approximate position
167,899,561) for line TZIKV-A, on chromosome 3 (at approxi-
mate position 402,525,313) for line TZIKV-B, on chromo-
some 3 (at approximate position 173,647,983) for line
TZIKV-C, and on chromosome 1 (at approximate position
228,972,549) for line TZIKV-D when aligned to the AaegL5
assembly (GenBank assembly accession no. GCA_002204515.1)
(36). To avoid any bias due to position effect variegation stem-
ming from transgene insertion sites, all four lines were screened
for midgut infection status at 4 days postinfection (dpi), and re-
sults showed that all four lines had significant reduction in midgut
infection rate and viral titers compared with Higgs or Liverpool
WT mosquitoes (SI Appendix, Fig. S2). Given that there was no
significant difference in ZIKV reduction in midgut infection be-
tween the four lines (TZIKV-A, TZIKV-B, TZIKV-C, and
TZIKV-D), the line exhibiting the strongest antiviral phenotype
(TZIKV-C) was selected for further comprehensive character-
ization (SI Appendix, Fig. S2).
Molecular Analysis of Synthetic Small RNA Expression and Processing.
To confirm expression and processing of the ZIKV-targeting
synthetic small RNAs in TZIKV-C, we deep-sequenced small
RNA populations from dissected midgut tissues isolated from
blood-fed and non–blood-fed female mosquitoes using an Illu-
mina platform. We detected expression of the nonguide (37) and
mature small RNA guide strands of five of eight anti-ZIKV–
targeting synthetic small RNAs (small RNAs 1, 2, 4, 6, and 8) with
transcripts per million values for mature small RNA guide strands
ranging from 2 to 91, 25.7 on average, indicating that these synthetic
small RNAs are efficiently expressed and processed (SI Appendix,
Fig. S3 and Table S1). Importantly, no anti-ZIKV–targeting small
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Fig. 1. Schematic of anti-ZIKV transgene, ZIKV target sites, and phenotype of
transgenic mosquitoes. (A) Schematic of the anti-ZIKV transgene used in the
study, consisting of a CPA (AAEL010782) promoter driving expression of a
polycistronic cluster of eight synthetic small RNAs engineered to target con-
served genes in the ZIKV genome. Following processing, the small RNAs and
their target ZIKV viral RNA interact in the cytoplasm. (B) Schematic of the ZIKV
genome, consisting of three structural proteins [capsid, membrane precursor
(prM), and envelope (E)] and seven nonstructural proteins (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5), with relative synthetic small RNA targets indicated
by hairpins above. (C) Higgs WT and TZIKV-C adult mosquitoes were imaged
under both transmitted light and a fluorescent dsRED filter. Fluorescence is
evident in mosquito eyes (indicated by white arrow).
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RNAs (more than one read) were identified in small RNA pop-
ulations derived from Higgs WT Ae. aegypti (SI Appendix, Table S1).
We also performed RT-PCR assays on dissected midgut tissues
and midgut-free carcasses from blood-fed and non–blood-fed fe-
male mosquitoes to determine whether synthetic small RNA ex-
pression was confined to the midgut. Contrary to previously
published reports (33, 38), we found that the CPA promoter drove
detectable expression of the synthetic small RNAs in tissues other
than the midgut and that expression occurred even without a blood
meal (SI Appendix, Fig. S4), suggesting that expression of the anti-
ZIKV transgene may be strongly affected by its genomic insertion
position. However, importantly, no anti-ZIKV–targeting small
RNAs were detected in Higgs WT Ae. aegypti (SI Appendix, Fig.
S4). Taken together, these results demonstrate that the anti-ZIKV
transgene is stably integrated into the mosquito genome and most
of the ZIKV-targeting synthetic small RNAs are expressed and
processed in an appropriate context (including in the midgut) for
ZIKV suppression.
Engineered Mosquitoes Are Refractory to Multiple ZIKV Strains. To
characterize the functional significance of ZIKV-targeting synthetic
small RNA expression and processing on vector competence, adult
female mosquitoes (Higgs WT control and TZIKV-C) were infected
with ZIKV (FSS13025, Cambodia 2010 strain; GenBank accession
no. JN860885) via membrane blood feeding (39). For these experi-
ments, we used the Cambodia ZIKV strain, which is from the Asian
ZIKV lineage and in close phylogenetic proximity to the French
Polynesia ZIKV strain against which the small RNAs were designed
(40). Importantly, seven of eight of the ZIKV-targeting synthetic
small RNA target sites are 100% conserved between the Cambodia
ZIKV strain and the French Polynesia strain, allowing either strain to
be used for the ZIKV challenges (SI Appendix, Fig. S1). At 4 dpi,
midguts from blood-fed mosquitoes were dissected and ZIKV RNA
copies were measured using real-time RT-qPCR. Results from three
biological replicates revealed that none of the TZIKV-C mosquitoes
homozygous for the transgene (n = 32) were positive for ZIKV in-
fection in the midgut. ZIKV infection was detected in 87.5% (28 of
32) of the TZIKV-C mosquitoes that were heterozygous for the
transgene; however, these mosquitoes had significantly (P < 0.001)
lower viral RNA levels (∼2 logs) than Higgs WT (Fig. 2A and SI
Appendix, Table S2).
To assay for viral dissemination, total RNA was collected from
whole TZIKV-C mosquito carcasses and dissected midguts from
both homozygous and heterozygous transgenic mosquitoes at 14
dpi. The results from three biological replicates indicated that
none of the homozygous TZIKV-C mosquitoes (n = 46) were
positive for viral replication (dissemination) in either the midgut
or the carcass. ZIKV prevalence was detected in 74.4% (29 of
39) of heterozygous TZIKV-C mosquitoes in both the carcass
and midgut; however, they had significantly (P < 0.001) lower
levels of viral RNA (∼3 logs) compared with Higgs WT mos-
quitoes (Fig. 2 B and C and SI Appendix, Table S2). Finally, to
determine viral transmission, saliva from individual mosquitoes
was collected at 14 dpi and ZIKV titers were measured using a
median tissue culture infectious dose assay. No ZIKV was de-
tected in the saliva of homozygous TZIKV-C mosquitoes (n =
46). The presence of ZIKV in the saliva was detected in 74.4%
(29 of 39) of heterozygous TZIKV-C mosquitoes; however, here
again, the ZIKV titers were significantly (P < 0.001) lower (∼3
logs) compared with Higgs WT mosquitoes (Fig. 2D and SI
Appendix, Table S2).
To determine whether the synthetic small RNAs are broadly
inhibitory for ZIKV, vector competence of transgenic TZIKV-C
mosquitoes was also assessed using a second contemporary
ZIKV strain (PRVABC59, isolated from a US traveler to Puerto
Rico in 2015; GenBank accession no. KU501215). For this
Fig. 2. ZIKV replication and titers in Higgs WT, TZIKV-C, andWolbachia-infected mosquitoes challenged with either a Cambodian or Puerto Rican ZIKV strain.
ZIKV genome copies and titers in Higgs WT, TZIKV-C homozygous (Hm) and heterozygous (Ht) transgenic, and Wolbachia-infected Higgs WT (Higgs-wMel)
mosquitoes following a blood meal infected with a Cambodian (FSS13025, A–D) or Puerto Rican (PRVABC59, E–H) strain of ZIKV are shown. ZIKV genome-
equivalents from mosquito midgut [4 dpi (A and E) and 14 dpi (B and F)] and carcass [14 dpi (C and G)] of Higgs WT and transgenic mosquitoes were de-
termined using real-time RT-qPCR and calculated using previously published methods. (D and H) Virus titers in the saliva collected from Higgs WT and
transgenic mosquitoes at 14 dpi were determined using a median tissue culture infectious dose (TCID50) on Vero cells and plotted. Higgs WT mosquitoes (●),
TZIKV-C Hm transgenic mosquitoes (♦),TZIKV-C Ht mosquitoes (▲), and Higgs-wMel mosquitoes (▼) are shown. Horizontal bars represent the mean virus
titer. *P < 0.05; **P < 0.001. For each experiment, data from three replicates are pooled.
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strain, seven of eight ZIKV-targeting synthetic small RNA target
sites (although not the same seven as for the Cambodia strain)
are 100% conserved with the French Polynesia strain against
which the small RNAs were designed (SI Appendix, Fig. S1).
Tests for infection, dissemination, and transmission were carried
out as above, and the results were comparable to those obtained
with the Cambodia strain. Briefly, at 4 dpi, none of the TZIKV-C
mosquitoes homozygous for the transgene (n = 32) were positive
for ZIKV infection in their midgut, and while ZIKV infection
was detected in 81.25% (26 of 32) of the TZIKV-C mosquitoes
that were heterozygous for the transgene, these had significantly
(P < 0.001) lower viral RNA levels (∼2 logs) than Higgs WT
mosquitoes (Fig. 2E and SI Appendix, Table S2). TZIKV-C
mosquito carcasses and dissected midguts at 14 dpi showed
that none of the homozygous TZIKV-C mosquitoes (n = 70)
were positive for viral replication in either the midgut or the
carcass by real-time RT-qPCR, while 70% (49 of 70) of het-
erozygous mosquitoes had ZIKV in both the carcass and midgut,
albeit with significantly (P < 0.001) lower levels of viral RNA (∼3
logs) than Higgs WT mosquitoes (Fig. 2 F and G and SI Ap-
pendix, Table S2). Finally, ZIKV titer measurements on saliva
from individual mosquitoes at 14 dpi demonstrated that no
ZIKV was present in homozygous TZIKV-C mosquitoes (n =
70), indicating that they would be unable to transmit the virus.
Prevalence of ZIKV in saliva was detected in 70% (49 of 70) of
TZIKV-C heterozygous mosquitoes; however, here again, the
ZIKV titers were significantly (P < 0.001) lower (∼3 logs)
compared with Higgs WT mosquitoes (Fig. 2H and SI Appendix,
Table S2).
Engineered Mosquitoes Outperform Wolbachia. We next compared
the inhibitory effect of our synthetic small RNAs with ZIKV in-
hibition previously shown with Wolbachia (13, 41–43). Vector
competence results revealed that midguts from mosquitoes (Higgs
WT strain) infected with Wolbachia (wMel strain, n = 50) had
significantly (P < 0.001) reduced ZIKV (Puerto Rican strain) RNA
levels (∼2 logs) at 4 dpi compared with uninfected Higgs WT
mosquitoes (n = 32; Fig. 2E and SI Appendix, Table S2). Similarly,
viral dissemination at 14 dpi was also reduced (P < 0.001) in wMel
mosquitoes (∼3 logs, n = 50; Fig. 2 F andG and SI Appendix, Table
S2), and ZIKV titers in mosquito saliva at 14 dpi were significantly
(P < 0.01) lower (∼2 logs) in wMel mosquitoes than in uninfected
Higgs WT mosquitoes (Fig. 2H and SI Appendix, Table S2). Im-
portantly, comparison with the TZIKV-C mosquitoes revealed that
the TZIKV-C mosquitoes are significantly (P < 0.001) more ef-
fective as homozygotes, and modestly more effective as heterozy-
gotes (P < 0.05), at blocking ZIKV infection compared with
Wolbachia-infected mosquitoes.
Anti-ZIKV Transgene Inhibits ZIKV Transmission in a Mouse Model. To
further characterize ZIKV inhibition by the anti-ZIKV transgene,
we also conducted limited tests of in vivo transmission capacity on
heterozygous TZIKV-C mosquitoes. Specifically, we utilized a very
sensitive STAT knockout (Stat1−/−) mouse model in which chal-
lenge with ZIKV (either intraperitoneally or via feeding by an in-
fected mosquito) rapidly causes systemic infections presenting high
viremia, resulting in significant weight loss, brain infections, and
mortality (44). First, we infected adult female mosquitoes (Higgs
WT and TZIKV-C) with Puerto Rican ZIKV strain (PRVABC59)
via thoracic injection, which bypasses the midgut barrier, resulting in
a significant viral titer in mosquitoes (44). At 7 dpi, TZIKV-C (n =
28) and Higgs WT (n = 29) mosquitoes were separately pooled into
four groups (with six to 12 individuals per group; Fig. 3A), and each
group was allowed to blood-feed on a Stat1−/− mouse, after which
mouse weight and survival were measured daily. All mice fed on by
infected Higgs WT mosquitoes (n = 4) became viremic and died
before 8 dpi with significant weight loss before death (P < 0.05; Fig.
3 B and C). Conversely, of the four mice fed on by TZIKV-C
mosquitoes, only one showed mortality (albeit at a later date, 12
dpi), and no significant weight loss was observed compared with the
control group (P < 0.0001; Fig. 3 B and C). Measurement of ZIKV
titers in the individual mosquitoes utilized for this assay demon-
strated that nearly all TZIKV-C mosquitoes had significantly re-
duced viral titers (∼2 logs) at 7 dpi compared with Higgs WT
mosquitoes (P < 0.0001; Fig. 3A).
To better simulate how mosquitoes naturally obtain patho-
gens (i.e., from blood feeding), we also performed the above
assay with mosquitoes that were infected with ZIKV (strain
PRVABC59) via oral membrane blood feeding, and obtained
similar results. Specifically, at 14 dpi via oral membrane blood
feeding, TZIKV-C (n = 16) and Higgs WT (n = 20) mosquitoes
were pooled into groups of six to 10 and allowed to feed on, and
transmit the virus to, Stat1−/−mice (n = 2 for each transgenic and
Higgs WT mosquito; Fig. 3D). The mice fed on by infected Higgs
WT mosquitoes experienced significant weight loss and mortality
before 8 dpi (P < 0.0001; Fig. 3 E and F). Conversely, mice fed
on by TZIKV-C mosquitoes showed no significant change in
weight and no infection-associated mortality (P < 0.0001; Fig. 3
E and F). Viral titer assays on these mosquitoes (at 14 dpi) in-
dicated that the ZIKV infection rate was dramatically reduced in
TZIKV-C mosquitoes (39% of mosquitoes infected compared
with 93% of Higgs WT mosquitoes; Fig. 3D) and that viral titers
of the TZIKV-C mosquitoes that were infected were signifi-
cantly lower (∼2 logs) than those of Higgs WT mosquitoes (P <
0.0001; Fig. 3D). Altogether, these results demonstrate that the
anti-ZIKV transgene confers robust refractoriness to ZIKV in-
fection and transmission, and that even mosquitoes heterozygous
for the transgene are unlikely to be able to transmit the virus.
Impact of Anti-ZIKV Transgene on Mosquito Fitness. Finally, to de-
termine whether the anti-ZIKV transgene had any significant fitness
effects on transgenic mosquitoes, we assessed several fitness pa-
rameters, including larval-to-pupal development time, male and
female fecundity and fertility, male mating success, adult wing
length (as a proxy for body size), and longevity (SI Appendix, Table
S3). No significant differences between Higgs WT and TZIKV-C
mosquitoes were observed when examining male mating success,
fecundity, and fertility (all P > 0.9); female fecundity (P > 0.05); and
male and female wing length (P > 0.05). Conversely, we observed a
significant difference (P < 0.01) in hatching rates of eggs laid by
Higgs WT versus TZIKV-C female mosquitoes (with the latter
having lower hatching rates) and a significant difference between
larval-to-pupal development time (P < 0.01), with TZIKV-C indi-
viduals developing faster. When assessing adult mosquito survivor-
ship, no significant differences were observed between Higgs WT
and TZIKV-C male mosquitoes (P > 0.05; SI Appendix, Fig. S5 and
Table S3), while Higgs WT female mosquitoes survived slightly
longer than TZIKV-C female mosquitoes (P < 0.0001; SI Appendix,
Fig. S5 and Table S3). Furthermore, there was no significant dif-
ference in survival at 14 dpi between Higgs WT and TZIKV-C
mosquitoes infected with the Cambodia ZIKV strain (P > 0.05;
SI Appendix, Table S4) and, similarly, no significant difference in
survival between Higgs WT, Higgs wMel-infected, and TZIKV-C
mosquitoes infected with the Puerto Rico ZIKV strain (P > 0.05; SI
Appendix, Table S4). Based on the above observations, it appears
that although the anti-ZIKV transgene did negatively affect female
mosquito longevity and egg-hatching rate, it did not result in sig-
nificant changes to most fitness parameters measured, including
fecundity and fertility, male mating success, and body size.
Discussion
Taken together, our results demonstrate that targeting conserved
genes in the ZIKV genome by expressing an engineered poly-
cistronic cluster of synthetic small RNAs confers to homozygous
mosquitoes complete refractoriness to multiple strains of ZIKV
infection, dissemination, and transmission. Although incomplete,
heterozygous mosquitoes also display partial refractoriness to
ZIKV infection, dissemination, and transmission, with significant
reduction of viral titers in the saliva (>2 logs compared with
WT). This significant reduction of ZIKV is greater than the viral
inhibition effect of Wolbachia, and may be sufficient to ensure
these heterozygous mosquitoes are unable to transmit ZIKV to a
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susceptible host. Indeed, this latter point is supported by our
finding that heterozygotes were largely unable to transmit
ZIKV to immunocompromised (Stat1−/−) mice after infection
via thoracic injection, and completely unable to transmit ZIKV
after infection via membrane feeding. As intrathoracic injection
generates unnaturally high infection levels by bypassing the
mosquito midgut and lumen barriers (44), it is perhaps un-
surprising that one mouse (possibly fed on by one of the mos-
quitoes with relatively high viral titers; Fig. 3A) experienced
ZIKV-associated mortality. However, the observation that
most of the heterozygous anti-ZIKV mosquitoes infected via
thoracic injection, and all of the mosquitoes infected via mem-
brane feeding, were unable to transmit ZIKV to a susceptible
mouse model strongly suggests that even heterozygotes are un-
likely to be capable of ZIKV transmission in the wild.
While the robust resistance observed in thoracic injection
experiments may seem unexpected because this method of in-
fection bypasses the midgut, where the CPA promoter is ca-
nonically expected to drive expression, our RT-PCR data
indicated that the anti-ZIKV small synthetic RNAs were
expressed in tissues other than the midgut. This is likely due to
genomic position effects, which have been previously observed
with this promoter (38), and could be addressed in future
work by optimization of midgut-specific expression [although
RNA-sequencing data indicate that CPA is actually expressed in
multiple tissues other than the midgut across various de-
velopmental time points (36, 45), and the CPA promoter may
therefore also act systemically].
Previously in Ae. aegypti, resistance to DENV has been
engineered by transgenic activation of antiviral pathways (26),
transgene-based RNAi in either the midgut (27, 46) or salivary
glands (28), and antiviral hammerhead enzymes (47), and
expression of synthetic miRNAs has also been demonstrated to
induce partial resistance to DENV-3 and CHIKV (32). However,
similar approaches have not been successfully demonstrated for
ZIKV, and the currently described system is potentially espe-
cially advantageous since targeting six of 10 conserved protein-
coding genes from the ZIKV genome with eight separate syn-
thetic small RNAs may reduce the possibility of escapee mutants,
and thus ensure evolutionary stability.
That said, it remains uncertain how many synthetic small RNAs
are necessary to ensure robust disease refractoriness and evolu-
tionary stability in a wild population. In our small RNA-sequencing
efforts, we only detected expression/processing of five of the eight
synthetic small RNAs, suggesting that perhaps the small RNA
processing machinery is overloaded, that the CPA promoter is not
strong enough to ensure robust expression from all eight synthetic
small RNAs, or that some synthetic small RNAs are possibly un-
stable and get quickly degraded after processing. The latter hy-
pothesis is supported by the fact that expression was only detected
from synthetic small RNAs 1, 2, 4, 6, and 8, while synthetic small
RNAs 3, 5, and 7 were undetected; given that these are arranged
numerically in a linear array (i.e., small RNAs 1–8), small RNAs 3,
5, and 7 must have been expressed/processed in order for small
RNAs 4, 6, and 8 to be expressed/processed/detected. Moreover,
contrary to expectations when using a blood meal-inducible pro-
moter such as CPA, levels of multiple synthetic small RNAs were
lower in post–blood meal-fed transgenic samples than in nonblood-
fed ones. The lack of clear blood meal expression induction is not
inconsistent with previous findings regarding use of the CPA pro-
moter to drive transgene expression (38), and likely arises due to
genomic position effects associated with the transgene integration
site. In any case, even without full expression driven by the CPA
promoter, it is clear that synthetic small RNA levels are sufficient
Fig. 3. Effect of anti-ZIKV transgene on ZIKV transmission in a mouse model. Higgs WT and heterozygous TZIKV-C mosquitoes were infected with Puerto
Rican ZIKV strain PRVABC59 thoracically (A–C) or orally (D–F), and assayed for their ability to transmit ZIKV to immunocompromised Stat−/−mice. Viral titers in
carcasses of mosquitoes infected thoracically (A, measured at 7 dpi) and orally (D, measured at 14 dpi) were determined by plaque assay in Vero cells and
plotted. Mean body weight (B and E) and survival (C and F) of Stat−/−mice following ZIKV infection by thoracically (B and C) or orally (E and F) infected Higgs
WT and TZIKV-C mosquitoes were measured and plotted. For all plots, white shapes represent results from Higgs WT mosquitoes and red shapes represent
TZIKV-C mosquitoes. For viral titer plots, horizontal bars represent the mean virus titer and vertical bars represent SEM. For mean body weight plots, vertical
bars represent SEM. ***P < 0.0001.
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enough to bring about robust ZIKV resistance in multiple genetic
backgrounds. However, future efforts should be focused on
addressing the above-mentioned open questions regarding small
RNA processing and specificity of expression.
Altogether, this strategy may provide a suitable cargo gene for
practical use with a gene drive system to reduce/eliminate vector
competence of mosquito populations. For example, previous reports
have shown that Cas9-mediated, homing-based gene drive can be
used for population modification of the malaria vector mosquito,
Anopheles stephensi (22), and it should be possible to develop similar
systems in Ae. aegypti. Given that homing-based drive systems quickly
convert heterozygotes into homozygotes (4), linking the anti-ZIKV
transgene described here to such a system could quickly convert an
entire mosquito population into anti-ZIKV homozygotes that would
be 100% resistant to ZIKV transmission. Recent ZIKV outbreaks
have shown that vector control remains an essential part of reducing
the health burden of emerging arboviruses. Although the aim of this
study was to illustrate the feasibility of producing ZIKV-refractory
mosquitoes, similar genetic engineering strategies could be used to
develop [or improve on (32)] single transgenes that render mosqui-
toes completely resistant to multiple arboviruses like DENV and
CHIKV. Given the increasing incidence of these viral infections
worldwide, such transgenes (coupled with gene drive systems) can
provide an effective, sustainable, and comprehensive strategy for re-
ducing the impact of arboviral mosquito-borne diseases.
Methods
Mouse Experiments. All mouse-related experiments were conducted in compli-
ance with the guidelines of the Laboratory Animal Center of National Health
Research Institutes (NHRI) in Taiwan. The animal protocol (NHRI-IACUC-105111)
was approved by the Institutional Animal Care and Use Committee of the
NHRI, according to the Guide for the Care and Use of Laboratory Animals (48).
Management of animal experiments and animal care and use practices of the
NHRI have been accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care International.
Data Availability Statement. All sequencing data associated with this study
are available from the National Center for Biotechnology Information
Sequence Read Archive (accession no. SRP150144, BioProject accession no.
PRJNA475410). The complete annotated plasmid sequence and DNA are
publicly available at Addgene (plasmid no. 104968). Transgenic mosquitoes
will be made available by the corresponding author upon request.
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